E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Disorders of consciousness as unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS) after a coma due to acquired brain injury. |
Troubles de la conscience tels que le syndrome d'éveil non repondant (ENR) et l'état de conscience minimale (ECM) après un coma dû d'une lésion cérébrale acquise. |
|
E.1.1.1 | Medical condition in easily understood language |
Disorders of consciousness |
Troubles de l'état de conscience |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This clinical trial aims to evaluate the efficacy of oral psilocybin for the treatment of patients with disorders of consciousness (DoC) after a coma and assess the prevalence of responders. |
Cet essai clinique vise à évaluer l'efficacité de la psilocybine par voie orale comme traitement pour les patients présentant des troubles de la conscience post-coma et mesurer la prévalence des répondeurs. |
|
E.2.2 | Secondary objectives of the trial |
This study aims to also better characterize the phenotype of potential good candidates to psilocybin treatment and identify a set of biomarkers that correlate with responsiveness (or non-responsiveness) to the therapy, as well to help underpinning the neural networks underlying the modulating action of psilocybin on consciousness and brain complexity. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pilot study on healthy participants: - Title: "Psilocybin to treat patients with post-comatose disorders of consciousness: pilot on healthy participants" -N: 20 subjects
Study on DoC patients: - Title: "Psilocybin to treat patients with post-comatose disorders of consciousness" - N: 30 patients |
|
E.3 | Principal inclusion criteria |
Inclusion criteria for healthy participants - 18-55 years old - No history of psychiatric, psychotic or neurologic disorders - No history of psychiatric disorders in first-degree relatives
Inclusion criteria for DoC patients - 18-55 years old - No history of psychiatric or psychotic in first-degree relatives - Clinically stable, not dependent on medical ventilators for respiration - Diagnosed as in an UWS or MCS according to the international criteria and based on at least 2 consecutive SECONDs/CRS-R - More than 28 days post-insult
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria for healthy participants: - Excessive use of alcohol (>30 units per week) - Renal failure - Coronary insufficiency - Pregnancy - Use of medication within the week before the experiment unless prescribed by general practitioner and with no interaction with the nervous system - History of stroke - Current angina - Uncontrolled hypertension - Abnormal electrical activity of the heart (ECG) (e.g. atrial fibrillation) - Artificial heart valve - Transient ischemic attack within the last year - Current epilepsy
Exclusion criteria: - History of previous neurological impairment other than related to their acquired brain injury - History of psychiatric or psychotic disorders - Renal failure - Coronary insufficiency - Contraindication to MRI, EEG, or PET (e.g., electronic implanted devices, external ventricular drain) - Use of serotoninergic agonists or antagonists (e.g., selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors) - Ritonavir (Norvir), an anti-retroviral medication used to treat HIV - Tricyclic antidepressants, such as amitriptyline and nortriptyline (Pamelor) - Monoamine oxidase inhibitors (MAOIs), antidepressants such as isocarboxazid (Marplan) and phenelzine (Nardil) - Current angina - Uncontrolled hypertension - Artificial heart valve - Transient ischemic attack within the last year - Pregnancy - Current epilepsy - Diabetes or obesity
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
New signs of consciousness assessed via the Simplified Evaluation of CONsciousness Disorders (SECONDs) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Two sessions separated by 5 days |
|
E.5.2 | Secondary end point(s) |
1-Change of complexity measured with the Lempel-Ziv Complexity 2-Changes in EEG spectral power within fixed bands or dynamic connectivity using median spectral connectivity and graph-theoretic topology metrics 3-Changes in the probability of consciousness using a multivariate EEG a classifier based on a machine-learning approach using 120 EEG markers 4-Difference of PET, MRI, or EEG in the baseline assessment between responders and not-responders |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Recording with EEG done from 20 minutes before giving psilocybin to a maximum of 150 minutes drug intake |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Theoretical proof-of-concept for link between complexity and consciousness |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last follow-up phone call of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |